News | August 10, 2024
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Nearly 200 participants from 50 Unani Academia and Council participated
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Subscribe To Our Newsletter & Stay Updated
